1-4 of 4
T. Kindler
Close
Sort by
Journal Articles

Results of a Multicenter Phase II Trial for Older Patients with c-Kit Positive Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Using Low-Dose Ara-C (LDAC) and Imatinib.

F. Heidel, MD, J. Cortes, MD, F. Ruecker, MD, M. Kaufmann, MD, W. Aulitzky, MD, L. Letvak, MD, T. Kindler, MD, C. Huber, MD, H. Dohner, MD, H. Kantarjian, MD, T. Fischer, MD
Journal: Blood
Blood (2005) 106 (11): 1853.
https://doi.org/10.1182/blood.V106.11.1853.1853
Published: 2005
Journal Articles

Clinical Course and Significance of the Novel FLT3-Y842C Mutation in a Patient with AML Treated with PKC412 Monotherapy.

T. Kindler, F. Breitenbuecher, S. Kasper, E. Estey, F. Giles, E. Feldman, G. Ehninger, G. Schiller, V. Klimek, S. D. Nimer, A. Gratwohl, C. Choudhary, C. Mueller-Tidow, H. Serve, H. Gschaidmeier, P. S. Cohen, C. Huber, T. Fischer
Journal: Blood
Blood (2004) 104 (11): 2537.
https://doi.org/10.1182/blood.V104.11.2537.2537
Published: 2004
Journal Articles

Mechanisms of Resistance to the FLT3-Tyrosine Kinase Inhibitor PKC412 in Patients with AML.

F. Heidel, F. Breitenbuecher, T. Kindler, F. K. Solem, B. Carius, H.-M. Thiede, P. S. Cohen, J. Roesel, E. H. Estey, E. Feldman, G. Ehninger, G. J. Schiller, V. Klimek, S. Nimer, D. DeAngelo, F. Giles, R. M. Stone, C. Huber, T. Fischer
Journal: Blood
Blood (2004) 104 (11): 454.
https://doi.org/10.1182/blood.V104.11.454.454
Published: 2004
Journal Articles

Durable Molecular Remissions in Patients with Relapsed CML Post Allogeneic Stem Cell Transplantation upon Treatment with Imatinib-Mesylate (Glivec®, STI-571). Follow-Up Results of a Phase II Open-Label Study.

G. Hess, MD, D. Bunjes, MD, W. Siegert, MD, R. Schwerdtfeger, MD, G. Ledderose, MD, B. Waßmann, MD, G. Kobbe, MD, M. Bornhäuser, MD, A. Hochhaus, MD, A. J. Ullmann, MD, T. Kindler, MD, H. Geschaidmeier, PhD, C. Huber11, MD, T. Fischer12, MD
Journal: Blood
Blood (2004) 104 (11): 1004.
https://doi.org/10.1182/blood.V104.11.1004.1004
Published: 2004